Amgen Announces Etelcalcetide Met Primary Endpoint of Non-Inferiority vs Cinacalcet

By: via Benzinga
Amgen (NASDAQ: AMGN) today presented the findings from a head-to-head Phase 3 study comparing intravenous etelcalcetide (AMG 416) with ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.